On the other hand, sPD-1 blocks PD-1/PDL-1 interactions (acts as an immune checkpoint blocker); higher plasma concentrations of sPD-1 in untreated anal and pancreatic ductal adenocarcinoma patients correlate with better prognosis (11). Here, HOXD13 is linked to pancreatic ductal adenocarcinoma.